Klin Onkol 2009; 22(4): 168-175.
Background: We evaluated the therapeutic results in 44 patients (17 girls and 27 boys) with osteosarcoma from 1997 to 2006. Their average age was
12.8 years (2.5– 20.2). 41 patients had localised disease and 3 had primary metastases.
Patients and Methods: We treated our 44 patients using CCG
7921 POG 9351 INT 0133, the therapeutic protocol of the North American cooperative Children’s Oncology Group. The median of the follow up was
5.5 years (2–11 years).
Results: 40 patients went into complete remission. 19 patients suffered relapses. Of these, 17 patients died – 15 progressed,
1 died due to treatment‑related toxicity, 1 died due to secondary acute myeloid leukaemia. As a whole, the patients had a 5-year overall survival
rate (OS) of 58.4% and a 5-year event free survival rate (EFS) of 46.7%. The patients with localised extremity osteosarcoma (n = 40) had a 5-year EFS
rate of 51%. The patients with good histological response (n = 22) had a 5-year EFS rate of 63.6%, while patients with poor histological response
(n = 18) achieved a 5-year EFS rate of 30.5% (p = 0.009).
Conclusion: The results of treatment of patients with localised extremity osteosarcoma and
patients with good histological response to preoperative treatment were very good. The prognosis of patients with axial localisation and metastatic
involvement was poor.
